ArticleBMC pulmonary medicine2026
Environmental exposures at home and in the workplace in relation to inhaled corticosteroid medication - the population-based REGAL study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiverse environmental exposures - home, occupational, and traffic-related - may impact asthma, but population-based studies on objectively assessed asthma are lacking. We aimed to investigate the impact of these exposures on future inhaled corticosteroid (ICS) use.
methodsData from two Swedish population-based cohorts (performed in 2008-2010) were linked to the National Prescribed Drug Registry from 2005 to 2018 to form the REGAL study. This analysis included 31,768 participants from Stockholm, Gothenburg, Uppsala, and Umeå. Participants reported asthma diagnosis, asthma-related symptoms, and home and occupational exposures via questionnaires, while ICS prescriptions were retrieved from registry.
resultsAmong 31,768 participants, 6.9% (n = 2,103) reported asthma medication via questionnaire at baseline, and 5.3% (n = 1,679) initiated ICS therapy during the follow-up period (median follow-up time: 10.7 years). The prevalence of floor dampness, irritating air at home, traffic exposure at home, and occupational exposure to gas, smoke, or dust were 3.8%, 17.9%, 4.0%, and 36.7%, respectively. Floor dampness (odds ratio OR = 1.32, 95%CI 1.06-1.63), irritating air (OR = 2.08, 95%CI 1.85-2.33), traffic exposure at home (OR = 1.48, 95%CI 1.21-1.81), and occupational exposure to gas, smoke, or dust (OR = 1.55, 95%CI 1.39-1.72) were associated with self-reported asthma medication. An increased risk of initiating ICS therapy during the follow-up period was found for floor dampness at home (hazard ratio HR = 1.42, 95%CI 1.14-1.77), irritating air at home (HR = 1.46, 95%CI 1.29-1.65), and previous occupational exposure to gas, smoke, or dust (HR = 1.25, 95%CI 1.12-1.40).
conclusionsIndoor dampness, irritating air at home, and occupational exposure to gas/smoke/dust were associated with self-reported asthma medication at baseline and future initiation of ICS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.